Phase 1 Trial Initiated for Product Candidate CAD-1883, Hoped to Provide Treatment for Spinocerebellar Ataxia and Essential Tremor
Novel therapeutics developer, Cadent Therapeutics (Cambridge, Massachusetts) has initiated a phase 1 clinical trial for product candidate CAD-1883, which is an allosteric modulator of the small conductance calcium-activated potassium (SK) channel. The drug is hoped to be a treatment for spinocerebellar ataxia and essential tremor.
Firing of cerebellar neurons that have SK channels is dysregulated in patients with spinocerebellar ataxia and essential tremor, which results in loss of motor control and impacts mobility and fine motor function. First in its class, CAD-1883 changes the calcium sensitivity of SK channels causing them to open at lower calcium concentrations. By lowering the threshold for SK channels to open, it is hoped that neuronal firing will be restored and that this in turn will improve motor function.
"This is an important step in the development of meaningful new therapies for people with movement disorders," said Michael Curtis, PhD, President and CEO of Cadent Therapeutics. "We have shown that allosteric modulation of the SK channel restores cadence to neuronal firing and is efficacious in disease models of ataxia and tremor. Our hope is that by precisely tuning dysregulated neuronal firing, we can reduce disability and restore motor function in patients with spinocerebellar ataxia and essential tremor."